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Summary Recently, a new FAD-dependent amine oxidase, renalase, was
described. It was secreted by the kidney into the blood and shown to have
signiﬁcant cardiovascular actions, which were attributed to its catechol-
amine-metabolising activity. The authors concluded that renalase might be
an important regulatory factor in human (patho)physiology. The catechol-
amine-metabolising activity of renalase in plasma contrasts with previous
investigations where catecholamines were found to be stable in human
plasma, provided autoxidation is prevented by an antioxidant. The claim
of catecholamine-metabolising activity of renalase was based on the gen-
eration of H2O2 during incubation of the enzyme with catecholamines.
Careful inspection and calculations of the data lead to the conclusion that
the rate of H2O2 generation is far too low to be ascribed to enzymatic
conversion of catecholamines by renalase. Renalase may well have impor-
tant cardiovascular functions, but there is no proof that its actions are me-
diated through catecholamine-metabolising activity.
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Introduction
Recently an intriguing paper described a new ﬂavin-adenine
dinucleotide (FAD) containing hormone, named renalase,
which is secreted by the kidney and circulates in blood
(Xu et al., 2005). Renalase was reported to be an amine
oxidase with signiﬁcant activity towards the catecholamines
noradrenaline (NA), adrenaline (ADR) and dopamine (DA),
but with little or no activity towards other physiologically-
occurring amines, such as serotonin, tyramine, benzyl-
amine, methylamine and spermidine. Although the amine
oxidase activity of renalase was dependent on its FAD con-
tent, it was insensitive to the FAD-containing monoamine
oxidase (EC 1.4.3.4) inhibitors pargyline and clorgyline.
Thus this reported amine oxidase activity of renalase dif-
fers in speciﬁcity and inhibitor-sensitivity from the known
FAD-containing amine oxidases. Renalase was shown to
have signiﬁcant cardiovascular actions when injected into
rats and these were ascribed to its catecholamine-metabo-
lising activity. In patients with end-stage renal disease,
renalase was found to be lacking from blood. The authors
suggested that the explanation for the increased frequency
of hypertension and cardiovascular dysfunction in these
patients might be the higher plasma catecholamine concen-
trations resulting from the absence of renalase. They con-
cluded that renalase might be an important regulatory
factor in human (patho)physiology.
Since the presence of this novel catecholamine-metabo-
lising enzyme in plasma is intriguing, but at variance with
our own experience, we took a closer look at previously
obtained data and at the evidence presented for the cate-
cholamine-metabolising activity of renalase.
Results and discussion
Plasma of many species contains an enzyme, named semi-
carbazide-sensitive amine oxidase (SSAO; E.C.1.4.3.6),
which catalyses the oxidative deamination of primary amines
to form the corresponding aldehydes plus H2O2 and ammo-
nia. The substrates converted depend on the species, but
generally include methylamine and aminoacetone, which
are believed to be the physiological substrates, as well
as benzylamine and 2-phenylethylamine (Boomsma et al.,
2003; Tipton et al., 2000). The SSAO in plasma of many
species is also able to oxidize DA, to a much lesser extent,
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e-mail: f.boomsma@erasmusmc.nlNA. ADR (a secondary amine) is not a substrate for SSAO
in any of the species investigated. For example, after incu-
bation of the catecholamines NA, DA and ADR in cow
plasma for 4h at 4C 95% of DA and 10% of NA had been
metabolised. After 4h at 20C virtually all DA and 42% of
NA had been metabolised. ADR was completely unchanged
after incubation at either temperature. In the presence of
semicarbazide, an inhibitor of SSAO, all conversions were
completely blocked, with no loss of any of the catechol-
amines being observed (Boomsma et al., 1993). These re-
sults indicate that there is no catecholamine metabolising
activity other than SSAO in plasma from this source.
The levels of SSAO in human plasma are relatively low
and do not cause signiﬁcant oxidation of any of the catechol-
amines. After incubation of NA, DA and ADR in human
plasma for 4h at either 4Co r2 0 C, all these catechol-
amines were found to be completely unaffected. The ab-
sence of oxidative activity towards DA was also conﬁrmed
by use of the radiochemical assay (Tipton et al., 2000) in
platelet-free human plasma.
Xu et al. (2005) based their claim of the catecholamine-
oxidising activity of renalase on the generation of H2O2,
detected by the Amplex Red Monoamine Oxidase Assay
Kit (from Invitrogen), during incubation of the enzyme
with NA, DA and ADR. The possibility that this activity
might be due to plasma ceruloplasmin can be excluded,
since the amine oxidase activity of that protein does not
produce H2O2. These results are at variance with our obser-
vations, reported above. However, non-enzymatic autoxida-
tion to which catecholamines are particularly prone at pH
values above neutrality does result in the loss of catechol-
amines and the formation of H2O2. This autoxidation may
be reduced by the addition of anti-oxidative agents, such as
ascorbic acid or glutathione, but Xu et al. (2005) do not
indicate that antioxidants were added in their experiments.
Inspection of the relevant ﬁgures in the paper by Xu
et al. (2005) showed that 3.1, 2.5 and 1.8nmol H2O2 were
formed per mg per min from DA, ADR and NA, respec-
tively, under the standard conditions of the assay that they
used. Since their assay mixture contained 10mg of recom-
binant renalase, 2mM catecholamines, with a 30min incu-
bation at 20C, that would mean that <1nmol of H2O2 is
formed from 400nmol of catecholamine, which would cor-
respond to a conversion of 0.25%. Thus, the possibility that
the observed H2O2 formation might arise from one or more
contaminants common to the three catecholamines (which
themselves have a purity of <97–98% when commercially
purchased) cannot be excluded.
Even if the formation of H2O2 were, indeed, caused by
oxidation of catecholamines by renalase, this is clearly a
very slow process. Unless the concentration of renalase in
plasma would be very high (there is no mention in the
paper of the actual concentrations) this could not have any
physiological relevance, certainly in view of the fact that
(patho)physiological plasma concentrations of catechol-
amines are at most a few nM for NA, and less than that
for DA and ADR, i.e. a million-fold lower than the con-
centrations used in the experiments of Xu et al. (2005).
Certainly, it is unlikely that effects seen in patients with
end-stage renal disease result solely from the absence of
such low catecholamine-oxidising activities or that the ef-
fects seen in the rat after injection of 0.5mg renalase (Xu
et al., 2005) were simply a response to this activity.
We conclude that it is highly unlikely that renalase is
a catecholamine-metabolising enzyme. The discovery of
renalase is an impressive piece of work, and renalase may
well have important cardiovascular functions, but these must
be mediated through another mechanism. The search for
the real substrate of this interesting ﬂavo-enzyme should be
continued.
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